102 related articles for article (PubMed ID: 25002745)
1. Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Chiba M
Drug Metab Dispos; 2014 Sep; 42(9):1485-92. PubMed ID: 25002745
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
[TBL] [Abstract][Full Text] [Related]
3. Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.
Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K
Pharmacol Res Perspect; 2013 Oct; 1(1):e00009. PubMed ID: 25505563
[TBL] [Abstract][Full Text] [Related]
4. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
5. Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.
Hosono H; Kumondai M; Maekawa M; Yamaguchi H; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2017 Mar; 45(3):279-285. PubMed ID: 27974382
[TBL] [Abstract][Full Text] [Related]
6. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Yamamiya I; Yoshisue K; Matsushima E; Nagayama S
Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005
[TBL] [Abstract][Full Text] [Related]
7. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
[TBL] [Abstract][Full Text] [Related]
8. Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur.
Murayama N; Sai K; Nakajima Y; Kaniwa N; Ozawa S; Ohno Y; Sawada J
Jpn J Cancer Res; 2001 May; 92(5):524-8. PubMed ID: 11376561
[TBL] [Abstract][Full Text] [Related]
9. Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.
Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K
J Pharm Pharmacol; 2014 Dec; 66(12):1686-97. PubMed ID: 25117829
[TBL] [Abstract][Full Text] [Related]
10. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
11. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.
Ozawa S; Hamada M; Murayama N; Nakajima Y; Kaniwa N; Matsumoto Y; Fukuoka M; Sawada J; Ohno Y
Cancer Chemother Pharmacol; 2002 Dec; 50(6):454-8. PubMed ID: 12451471
[TBL] [Abstract][Full Text] [Related]
12. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.
Wang H; Bian T; Liu D; Jin T; Chen Y; Lin A; Chen C
Pharmacogenomics; 2011 Apr; 12(4):481-92. PubMed ID: 21521021
[TBL] [Abstract][Full Text] [Related]
13. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
14. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).
Han S; Choi S; Chun YJ; Yun CH; Lee CH; Shin HJ; Na HS; Chung MW; Kim D
Biol Pharm Bull; 2012; 35(3):394-9. PubMed ID: 22382327
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of cytochrome P450 2A6 allelic variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22.
Tiong KH; Yiap BC; Tan EL; Ismail R; Ong CE
Drug Metab Dispos; 2010 May; 38(5):745-51. PubMed ID: 20139165
[TBL] [Abstract][Full Text] [Related]
18. Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids.
Uno T; Ogura C; Izumi C; Nakamura M; Yanase T; Yamazaki H; Ashida H; Kanamaru K; Yamagata H; Imaishi H
Biopharm Drug Dispos; 2015 Nov; 36(8):552-63. PubMed ID: 26222491
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective metabolism and pharmacokinetics of tegafur.
Damle BD; Narasimhan NI; Kaul S
Biopharm Drug Dispos; 2001 Mar; 22(2):45-52. PubMed ID: 11745907
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of 7-ethoxycoumarin, safrole, flavanone and hydroxyflavanone by cytochrome P450 2A6 variants.
Uno T; Obe Y; Ogura C; Goto T; Yamamoto K; Nakamura M; Kanamaru K; Yamagata H; Imaishi H
Biopharm Drug Dispos; 2013 Mar; 34(2):87-97. PubMed ID: 23112005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
